SCHEMBL6017765

SCHEMBL6017765

Cc1ccc(CNC(=O)c2nc(-c3ccccn3)n(C)c(=O)c2O)cc1C

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.41
MAPK1 P28482 2/20 0.41
HSD17B10 Q99714 1/20 0.41
KDM4E B2RXH2 2/20 0.41
LMNA P02545 2/20 0.41
TP53 P04637 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
AADAT Q8N5Z0 1/20 0.41
HIF1A Q16665 1/20 0.41
KCNE1 P15382 1/20 0.40
CCR1 P32246 1/20 0.40
KCNQ1 P51787 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ADORA3 P0DMS8 1/20 0.40
MMP1 P03956 1/20 0.39
MMP7 P09237 1/20 0.39
MMP9 P14780 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6017750 0.92 KDM4E (0.45) ALDH1A1MAPK1HSD17B10KDM4EHPGD
SCHEMBL6017740 0.89 KMT2A (0.47) ALDH1A1MAPK1HPGDAADATKCNE1
SCHEMBL6017761 0.89 CNR1 (0.47) HPGD
SCHEMBL6017770 0.89 SCD (0.44) ALDH1A1MAPK1SMN1; SMN2AADATKCNE1
SCHEMBL6017640 0.87 MEN1 (0.51) TP53HTTKMT2AMEN1
SCHEMBL6018991 0.87 SMN1; SMN2 (0.53) SMN1; SMN2KCNE1CCR1KCNQ1L3MBTL1
SCHEMBL6017795 0.87 MMP1 (0.50) ALDH1A1KCNE1CCR1KCNQ1MMP1
SCHEMBL6017674 0.84 SMN1; SMN2 (0.42) LMNAMAPTSMN1; SMN2KCNE1CCR1
SCHEMBL6017731 0.82 KCNE1 (0.37) ALDH1A1MAPK1HSD17B10KDM4ELMNA
SCHEMBL6018457 0.82 EGLN1 (0.47) ALDH1A1KDM4ELMNATP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040229892-A1 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex BRISTOL-MYERS SQUIBB COMPANY 2004-11-18 US claimed
US-7037908-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2006-05-02 US disclosed
US-20040229892-A1 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex BRISTOL-MYERS SQUIBB COMPANY 2004-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229892-A1 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex DUT, CDK6, TYMS ALDH1A1 633/4885MAPK1 2600/4885HSD17B10 2067/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.